Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$5.2 - $29.12 $15,600 - $87,360
-3,000 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$7.95 - $12.27 $9,540 - $14,724
1,200 Added 66.67%
3,000 $33,000
Q3 2019

Nov 12, 2019

BUY
$12.44 - $17.48 $22,392 - $31,464
1,800 New
1,800 $23,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Compagnie Lombard Odier S Cm A Portfolio

Follow Compagnie Lombard Odier S Cm A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

News

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.